Welcome to our dedicated page for CS Diagnostics SEC filings (Ticker: CSDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CS Diagnostics Corp. (CSDX) filings document the company's reporting status, audit timing and capital structure as a Wyoming-incorporated operating company. Its Form 12b-25 notice covers delayed Form 10-K preparation for the fiscal year ended December 31, 2025, including the need to complete financial statements and independent audit procedures.
Form 8-K disclosure records the completed conversion of Series B Preferred Stock held by CS Interpharm General Trading Co. LLC and CS Diagnostics Pharma GmbH into CSDX common stock. The filing describes the share issuance, the exemption from Securities Act registration, and the alignment of affiliate capital structures for consolidated financial reporting.
CS Diagnostics Corp. (CSDX) reported a quarter marked by a large intangible-asset acquisition funded by equity. The balance sheet shows $499,400,000 of intangible assets and $504,163,629 of additional paid-in capital with an accumulated deficit of $(4,735,665). Cash flows show $(345) net cash used in operating activities, $(499,444,401) used in investing largely for intangible asset purchases, and $499,444,401 provided by financing reflecting equity infusions and issuance of preferred shares. The company issued Series B preferred shares (19,992,575 outstanding) and shows common shares of 137,340,200 outstanding as of June 30, 2025. Net income for the period is noted as $196, and year-to-date changes include shares issued in connection with asset acquisition.
Antonio Santoli reports beneficial ownership of 13,596,680 shares of CS Diagnostics Corp. common stock, representing 9.9% of the class. That total includes 3,800,000 shares held directly and 9,796,680 shares issuable on conversion of Series B preferred stock, but conversion is limited by a 9.9% conversion cap in the Series B Certificate of Designation. The filing states the reported ownership excludes any additional Series B shares that cannot be converted due to that cap and excludes securities held in entities where the reporting person lacks voting or dispositive power. The filing also notes the issuer’s Preferred A shares carry supervoting rights representing over 90% of voting power, and the reporting person certifies the position is not held to change or influence control.
Thomas Graus filed a Schedule 13G reporting beneficial ownership of 13,392,434 shares of CS Diagnostics Corp. common stock, equal to 9.9% of the class as of the filing. The holding comprises 3,700,000 shares held directly and 9,692,434 shares issuable upon conversion of Series B preferred shares, although conversions are limited by a 9.9% cap in the Certificate of Designation. The filing states sole voting and dispositive power over the reported shares and excludes any securities held through entities where the filer lacks control. The filer certifies the stake was not acquired to change or influence control.
CS Diagnostics Corp. filed Amendment No. 1 to its Form 10 registration statement to register its common stock, par value $0.001 per share, under Section 12(g) of the Securities Exchange Act of 1934. The Wyoming corporation lists its principal executive offices in Neuss, Germany and classifies itself as a small reporting company.
The amendment primarily cross-references an information statement filed as Exhibit 99.1 for detailed disclosures on business, risk factors, financial information, ownership, governance, and executive compensation, and includes an amended financial period ending March 31, 2025 as an exhibit. The filing is signed on behalf of the company by Group CFO Mohammad EsSayed.
CS Diagnostics Corp. filed Amendment No. 1 to its Form 10 registration statement to register its common stock, par value $0.001 per share, under Section 12(g) of the Securities Exchange Act of 1934. The Wyoming corporation lists its principal executive offices in Neuss, Germany and classifies itself as a small reporting company.
The amendment primarily cross-references an information statement filed as Exhibit 99.1 for detailed disclosures on business, risk factors, financial information, ownership, governance, and executive compensation, and includes an amended financial period ending March 31, 2025 as an exhibit. The filing is signed on behalf of the company by Group CFO Mohammad EsSayed.
CS Diagnostics Corp. filed Amendment No. 1 to its Form 10 registration statement to register its common stock, par value $0.001 per share, under Section 12(g) of the Securities Exchange Act of 1934. The Wyoming corporation lists its principal executive offices in Neuss, Germany and classifies itself as a small reporting company.
The amendment primarily cross-references an information statement filed as Exhibit 99.1 for detailed disclosures on business, risk factors, financial information, ownership, governance, and executive compensation, and includes an amended financial period ending March 31, 2025 as an exhibit. The filing is signed on behalf of the company by Group CFO Mohammad EsSayed.